ÄúÏÖÔÚµÄλÖãºÊ×Ò³ ? ÐÂÎÅÖÐÐÄ ? ÐÐÒµ¶¯Ì¬
182ÌåÓý¹ÙÍø-¿ÆÑ§¼Ò·¢ÏÖÖÎÁƸ߼¶±ðÄÔ½ºÖÊÁöµÄÐÂ;¾¶
×÷Õߣº182ÌåÓý¼¯ÍÅ

¿ÆÑ§¼Ò·¢Ã÷Ò½Öθ߼¶±ðÄÔ½ºÖÊÁöµÄз×Ó

ÈÕÆÚ£º2023-05-10 À´Àú£º±¾Õ¾ ¹©¸å£º¹ú¼Ê»¥ÖúÓë»ùµØÆ½Ì¨´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ

ÄÔ½ºÖÊÁöÊÇ×î¶à¼ûµÄÔ­·¢ÐÔÄÔÖ×Áö£¬·¢Ô´ÔÚÄêÒ¹ÄÔµÄÉñ¾­½ºÖÊϸ°û¡£¾­Óɹý³ÌÔö³¤µÍÃܶÈÖ¬ÂѰף¨LDL£©ÇéÊÆµ¨¹Ì´¼ÉãÈëµÄ´úÐ»ÖØ±à³Ì£¬ÊǰüÀ¨¸ß¼¶±ðÄÔ½ºÖÊÁö£¨HGG£©ÓÚÄÚµÄÖ×Áöϸ°ûÁ¬½á¿ìËÙÉú³¤µÄÒ»ÖÖ·½Ê½£¬ÊÇÒÔ£¬LDLÊÜÌ壨LDLR£©»òÕ߿ɳÉΪÖ×ÁöÒ½ÖθÉÉæ¸ÉÓëµÄDZÓڰбꡣ½üÆÚ£¬Åµ¶¡ººÄêҹѧÓë¶Å¿ËÄêҹѧµÄÑо¿Ö°Ô±·¢Ã÷£¬ºÜ¶àÉÄÑøHGGµÄѪ¹ÜÉϺ¬Óи̶߳ȵÄLDLR¡£Ñо¿½á¹û·¢±íÓÚ¡¶Pharmaceutics¡·ÆÚ¿¯£¬±êÌâΪ¡°Low-Densi182ÌåÓý¹ÙÍø-ty Lipoprotein Pathway Is a UbiquitousMetabolic Vulnerability in High Grade Glioma Amenable for NanotherapeuticDelivery¡±¡£ Ñо¿Ö°Ô±ÓÚÓÉ36Àý³ÉÈ˼°133Àý¶ù¿ÆHGG»¼ÕßµÄÖ×ÁöÑù±¾½¨ÔìµÄ¹¹Ôì΢ÕóÁÐÉÏ£¬ÔËÓÃÃâÒß¹¹Ô컯ѧ¾ÙÐмì²â£¬Ñо¿³É¹û×¢½â£¬ÓÚ³ÉÈ˼°¶ùͯÐÐÁв½¶ÓÖдæÓڹ㷺µÄLDLR±í´ï£¬ÌáÐÑLDLRÊÇËù·áÄêÁä¶ÎHGGµÄÓÐÓÃÒ½Öΰеã¡£Ëæºó£¬Ñо¿Ö°Ô±¾­Óɹý³ÌÃâÒßÓ«¹â¼¼ÄÜ£¬ÆÀ¹ÀÁËÈýÖÖ½ºÖÊĸϸ°ûÁö¾­³£Ê¹ÓõÄϸ°ûϵÖÐLDLRµÄ±í´ï£¬Ñо¿³É¹û×¢½â£¬Óë³ÉÈËGIN28ϸ°ûϵ±ÈÄ⣬¶ù¿ÆSF188¼°KNS42ϸ°ûϵ¾ß±¸Ïà¶ÔÓڽϸߵÄLDLR±í´ï³Ì¶È£¬ÌáÐÑÕâЩϸ°ûϵ¿ÉÒÔÓÃÔÚ²âÊÔLDL½éµ¼µÄÄÉÃ׿ÅÁ£/Ò©ÎïµÝËÍÄ£×Ó¡£ ¸ÃÑо¿ÎªÄÔ½ºÖÊÁöµÄÐÂÁÆ·¨¼°ÓÃÔÚÄÔ½ºÖÊÁöÒ½ÖεϝÁÆÒ©ÎïµÄµÝËÍÌṩÁËÐÂ˼Ð÷¡£ ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶Pharmaceutics¡·ÆÚ¿¯Ô­ÎÄÕ£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È£¬½ö¹©²Î¿¼¡£-182ÌåÓý¹ÙÍø-

 

  • ÉÏÒ»ÌõµÚ¶þʮһ½ì£¨2024£©ÖйúÐóÄÁÒµ²©ÀÀ»áһƳ...
  • ÂÌÉ«ËÇÌí Ô­×°½ø¿Ú¡ª¡ªÓÅĬÉúÎïÔÚÄϾ©Öйú...ÏÂÒ»Ìõ
  • º¼ÖÝÊÐÎ÷ºþ¿Æ¼¼Ô°Õñ»ªÂ·206ºÅÎ÷¸Ûнç4´±D×ù5Â¥

    ÍøÕ¾µØÍ¼

    ÓëÓÅĬÉúÎï¿Í·þͨ»°

    0571-88957086

    ÁªÏµÓÅĬÉúÎ»ñÈ¡²úÆ·±¨¼Û

    Ò²¿ÉÒÔÁôÏÂÄúµÄµç»°£¬ÓÅĬÉúÎï¿Í·þ»áÓëÄúÁªÏµ

    ÐÅÏ¢±£»¤ÖÐÇë·ÅÐÄÌîд

    ÔÚÏß×Éѯ

    Ìá½»³É¹¦

    Çë±£³ÖÊÖ»ú³©Í¨£¬×¢Òâ½ÓÌýµç»°